KAS
SRPT icon

Kestra Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Kestra Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,165
Closed -$25.1K – 4257
2025
Q4 		$25.1K Buy
+1,165
New +$24.6K ﹤0.01% 4391
2024
Q3 		– Sell
-1,446
Closed -$228K – 2724
2024
Q2 		$228K Buy
+1,446
New +$186K ﹤0.01% 2309

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kestra Advisory Services's SRPT Position: Q1 2026 in Review

Kestra Advisory Services sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 1,165 shares — an estimated $25.1K sold.

Kestra Advisory Services first reported a position in SRPT in Q2 2024 and held it in 2 quarters. The position peaked at $228K in Q2 2024. 345 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Kestra Advisory Services reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 1,165 Sarepta Therapeutics shares in Q1 2026, an estimated $25.1K.
  • Kestra Advisory Services first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 2 quarters.
  • Kestra Advisory Services's Sarepta Therapeutics position peaked at $228K in Q2 2024.
  • 345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.